Ken Griffin’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$361K Sell
4,100
-39,300
-91% -$4.08M ﹤0.01% 10980
2026
Q2
$4.23M Buy
43,400
+11,600
+36% +$1.01M ﹤0.01% 5024
2026
Q1
$2.67M Buy
31,800
+21,000
+194% +$1.22M ﹤0.01% 5495
2025
Q4
$445K Sell
10,800
-37,900
-78% -$1.47M ﹤0.01% 9312
2025
Q3
$1.92M Buy
+48,700
New +$1.24M ﹤0.01% 6155
2025
Q2
– Sell
-8,900
Closed -$161K – 13054
2025
Q1
$161K Buy
8,900
+8,300
+1,383% +$183K ﹤0.01% 10752
2024
Q4
$13.1K Buy
600
+200
+50% +$5.14K ﹤0.01% 13462
2024
Q3
$11K Buy
+400
New +$11.1K ﹤0.01% 13178
2023
Q2
– Sell
-431
Closed -$5.48K – 14499
2023
Q1
$5.48K Buy
431
+181
+72% +$2K ﹤0.01% 13867
2022
Q4
$1.58K Buy
+250
New +$4.43K ﹤0.01% 14449
2022
Q1
– Sell
-694
Closed -$49K – 13770
2021
Q4
$49K Buy
+694
New +$69.8K ﹤0.01% 13260

Other funds holding DNTH

Ken Griffin's DNTH Position: Q3 2026 in Review

Ken Griffin reduced its Dianthus Therapeutics (DNTH) stake by 35% in Q3 2026, selling an estimated $35.9M and leaving 629,225 shares worth $55.4M. The position accounts for 0.01% of the portfolio, ranked #1461.

Ken Griffin first reported a position in DNTH in Q2 2018 and has held it in 28 quarters since. The position peaked at $135M in Q1 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Ken Griffin held 629,225 shares of Dianthus Therapeutics worth $55.4M as of Q3 2026.
  • Ken Griffin sold 345,686 Dianthus Therapeutics shares in Q3 2026, an estimated $35.9M.
  • Dianthus Therapeutics made up 0.01% of Ken Griffin's portfolio in Q3 2026, its #1461 holding.
  • Ken Griffin first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 28 quarters since.
  • Ken Griffin's Dianthus Therapeutics position peaked at $135M in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.